Form 4: Seres Therapeutics Director Paul Biondi Acquires 100,000 Stock Options
SEC Form 4
Director Paul Biondi reports acquisition of 100,000 stock options in Seres Therapeutics.
Summary
- On April 10, 2025, Paul Biondi, a director of Seres Therapeutics, acquired 100,000 stock options.
- The options have an exercise price of $0.58.
- The options vest fully on the earlier of April 10, 2026, or the day before the company's 2026 annual meeting of shareholders.
- The options expire on April 9, 2035.
- Following the transaction, Biondi directly owns 100,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing regarding stock option grants, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to align management's interests with those of shareholders.
Stakeholder Impact
- The granting of stock options to a director can align their interests with those of shareholders, potentially incentivizing them to increase company value.
Key Dates
| Date | Description |
|---|---|
| 04/10/2025 | Date of transaction: Paul Biondi acquired 100,000 stock options. |
| 04/10/2026 | Vesting date: Options vest fully on this date or the day before the 2026 annual meeting. |
| 04/09/2035 | Expiration date: Options expire on this date. |
| 04/11/2025 | Date of Form 4 filing. |
Keywords
stock options, Form 4, derivative securities, beneficial ownership, Seres Therapeutics, MCRB, Biondi, director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.